San Diego-based Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, has appointed N. Anthony Coles, M.D., to the company's board of directors.
Coles brings nearly 30 years of experience in the health care, biotechnology and pharmaceutical industries. Most recently, he served as president, CEO and chairman of the board of Onyx Pharmaceuticals, a global biopharmaceutical company that was acquired by Amgen in October 2013.
Prior to joining Onyx in 2008, Coles was president, CEO, and a member of the board of directors of NPS Pharmaceuticals Inc. Before that, he was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb, and from 1992 until 1996 he also held a number of positions of increasing responsibility at Merck & Co. Inc.
Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a cardiovascular research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University.
Dr. Coles is a member of the board of directors of McKesson Corp. He is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. Coles also serves as a member of the board of the U.S. Olympic and Paralympic Foundation.